This study tests if a drug called zoledronic acid (ZA) can help prevent bone fractures in people over 60 with Parkinson's disease or parkinsonism. Participants will be divided into two groups: one will receive ZA, and the other a placebo (a harmless substance that looks like the drug). The trial is "randomized," meaning participants are randomly assigned to a group, and "placebo-controlled," meaning the effects of ZA are compared to the placebo. Neither the participants nor the researchers will know who gets ZA. The study is conducted at home, avoiding extra medical visits, and lasts at least 2 years. Participants must be willing to take vitamin D and provide consent. They will have regular follow-ups every 4 months to check for fractures.
- This is a home-based study, lasting at least 2 years.
- Participants receive ZA or a placebo through a single infusion.
- No extra medical visits or BMD tests are needed.
How understandable was the trial content above?
Hard to understand
Easy to understand